
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics is poised for success due to its strong pipeline of investigational products, including its lead candidate sparsentan, which has shown promising results in treating rare kidney disorders like FSGS and IgAN. With its recent FDA approval and a potential expansion of exclusivity, the company's sales and earnings are expected to continue growing in the coming years. Furthermore, the recent convertible debt offering provides the company with financial flexibility to support its operations. Overall, Travere's unique market position and strong financials make it an attractive investment opportunity.
Bears say
Travere Therapeutics is facing upcoming competition from other companies in the rare kidney disease market, as well as potential setbacks in its commercial execution that could impact its stock negatively. The company's promising pipeline drug, Filspari, has shown demand in the IgA nephropathy (IgAN) market, but there is uncertainty about its potential success in the FSGS market as there are currently no identified major groups that would not use the drug. Additionally, the recent licensing deal for an early-stage asset may provide potential upside, but it also adds uncertainty to the company's plans and development timelines.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares